Trial Profile
A Dose-range Study to Assess the Safety and Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-month) in Healthy Adult Females (18-25 Years of Age)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 568893A (Primary) ; AS04A; Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 24 Mar 2014 Primary endpoint 'Geometric-mean-antibody-titre' has not been met.
- 24 Mar 2014 Results published in Vaccine.
- 12 Jun 2013 Planned number of patients changed from 376 to 383 as reported by ClinicalTrials.gov.